MannKind | MNKD - Operating Profit

Stock Price
2.56
Daily Change
-0.05 -1.92%
Monthly
-53.79%
Yearly
-51.33%
Q1 Forecast
2.69

MannKind reported $-69.24M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Adma Biologics USD 62.75M 11.74M Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
MacroGenics USD -12.1M 30.74M Dec/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD 6.24B 318M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Novavax USD 20.94M 100.32M Dec/2025
Novo Nordisk DKK 5.18B 33.61B Jun/2025
Pfizer USD 4.65B 3.99B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Xencor USD -53.63M 6.11M Dec/2025